Market open
vTv Therapeutics/$VTVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About vTv Therapeutics
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Ticker
$VTVT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23
ISIN
US9183852048
Website
vTv Therapeutics Metrics
BasicAdvanced
$55M
-
-$2.93
-
-
Price and volume
Market cap
$55M
52-week high
$29.01
52-week low
$12.12
Average daily volume
11K
Financial strength
Current ratio
7.395
Quick ratio
7.196
Total debt to equity
1.405
Management effectiveness
Return on assets (TTM)
-36.33%
Return on equity (TTM)
-131.31%
Valuation
Price to revenue (TTM)
7,897.109
Price to book
17.48
Price to tangible book (TTM)
17.48
Growth
Revenue change (TTM)
-98.30%
Earnings per share change (TTM)
-65.44%
3-year revenue growth (CAGR)
-84.98%
3-year earnings per share growth (CAGR)
-33.47%
What the Analysts think about vTv Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
vTv Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
vTv Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
vTv Therapeutics News
AllArticlesVideos
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
GlobeNewsWire·6 hours ago
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
GlobeNewsWire·4 days ago
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for vTv Therapeutics stock?
vTv Therapeutics (VTVT) has a market cap of $55M as of May 19, 2025.
What is the P/E ratio for vTv Therapeutics stock?
The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of May 19, 2025.
Does vTv Therapeutics stock pay dividends?
No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of May 19, 2025.
When is the next vTv Therapeutics dividend payment date?
vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.
What is the beta indicator for vTv Therapeutics?
vTv Therapeutics (VTVT) does not currently have a Beta indicator.